ABEO

SEC Filing Summary: Access Pharmaceuticals, Inc. (10-Q)

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2009. Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company focused on nanopolymer chemistry and drug delivery technologies. The company's portfolio includes one FDA-approved product (MuGard for oral mucositis), one Phase 3 candidate (ProLindac for cancer), and several pre-clinical and Phase 1/2 candidates. On February 25, 2009, the company completed the acquisition of MacroChem Corporation via a pooling-of-interest transaction due to common control.

Key Financial Metrics

Liquidity: The net cash burn rate for the six months ended June 30, 2009, was approximately $241,000 per month. Management expects current capital resources to fund operations into the first quarter of 2010.

Material Changes vs. Prior Period

• Revenue: Total revenue decreased by $66,000 (39%) compared to the prior six-month period, primarily due to the absence of $131,000 in sponsored research and development income received in 2008. Licensing revenue increased from $39,000 to $104,000.
• Expenses: Total operating expenses decreased significantly by $21,141,000 (84%). This reduction is largely attributable to the absence of one-time non-cash in-process research and development (IPR&D) charges recorded in 2008 related to the acquisitions of Somanta ($8.9M) and Virium ($9.7M).
• Net Loss: The net loss allocable to common stockholders decreased by $22,404,000 (81%) due to the reduction in operating expenses and the elimination of prior-year acquisition-related charges.
• Debt: MacroChem notes payable were exchanged and cancelled for common stock in connection with the February 2009 acquisition, reducing interest expense.

Outlook, Risks, and Management Commentary

• Going Concern: The company has incurred significant losses since inception and has a working capital deficit. Management states that capital resources may not be sufficient to achieve long-term goals and that additional financing will likely be required within the next twelve months.
• Internal Controls: Management concluded that disclosure controls and procedures were not effective as of June 30, 2009, due to a material weakness in the monitoring and review of financial reporting (lack of segregation of duties and accounting staff). This weakness has not been remediated.
• Dividends and Defaults: The company accrued $1,866,000 in preferred stock dividends payable as of June 30, 2009. Additionally, $992,000 in liquidated damages was accrued due to the failure to maintain an effective registration statement for preferred stock conversions as required by an Investor Rights Agreement.
• Recent Developments:
  • Commenced a new clinical study of ProLindac in France (August 2009).
  • Evaluating strategic options for commercializing MuGard in North America.
  • Received $1,000,000 in license receipts after the quarter closed (August 2009).

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.23M cash balance against the $241k/month burn rate to confirm the ability to operate into Q1 2010 without immediate dilution or debt restructuring.
• Debt and Dividend Obligations: Confirm the status of the $5.5M convertible note due September 2011 and the $1.866M accrued preferred dividends, including the risk of further liquidated damages if the registration statement is not declared effective.
• Internal Control Remediation: Assess the timeline and plan for hiring accounting staff to address the material weakness in internal controls over financial reporting.
• Licensing Revenue Sustainability: Evaluate the reliance on licensing fees (e.g., the $1M post-quarter receipt) versus the lack of product sales revenue to fund ongoing R&D.
• Acquisition Accounting: Review the pooling-of-interest accounting treatment for the MacroChem acquisition to ensure comparability of financial data with prior periods.